Accelrys to Enhance Breadth and Usability of its Life Science Modeling and Simulation Environment with Discovery Studio(R) 1.7.Pharmacophore pharmacophore the group of atoms in the molecule of a drug responsible for the drug's action. Modeling Functionality, Components for Workflow Creation, a Customizable Interface, and Scripting Capabilities Contribute to Ease of Use and Effectiveness SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- Accelrys, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ACCL ACCL American Canadian Caribbean Line ACCL Acceleration ACCL American College of Construction Lawyers ACCL Accreditation Council for Clinical Lipidology (Allied Health Certification Program) ACCL Amway China Co Limited ), a leading provider of scientific software and services, announced today that it will expand its Discovery Studio software environment with new and enhanced life science modeling and simulation functionality, including pharmacophore modeling and Perl scripting capabilities that will be accessible from Discovery Studio for the first time. Discovery Studio 1.7 will also include new component collections for creating complex pharmacophore modeling and simulation workflows within SciTegic Pipeline Pilot, the Accelrys scientific operating platform. The new pharmacophore modeling functionality will contain tools for alignment-based pharmacophore mapping, fast conformer generation, and structure-based pharmacophore generation. Novel CHARMm-based protein side-chain and loop refinement methods and a physics-based binding affinity estimation method will also be part of Discovery Studio 1.7, as will key functionality from other widely-used Accelrys applications. New tools for customizing the graphical interface See GUI. of Discovery Studio and automating molecular data analysis workflows with Perl scripting will also be included. Discovery Studio 1.7 will provide new component collections for pharmacophore modeling (Catalyst) and simulation (CHARMm). Users will be able to plug these components into workflows created within the SciTegic Pipeline Pilot platform, where they will be able to easily build and automate complex data analysis workflows. With the openness of the SciTegic Pipeline Pilot platform, workflows can include components developed by customers or Accelrys' Independent Software Vendor partners. Results output from Pipeline Pilot can then be visualized and analyzed in the powerful graphical environment of Discovery Studio. The company provided samples of the beta version A pre-shipping release of hardware or software that has gone through alpha test. A beta version of software is supposed to be very close to the final product, but, in practice, it is more a way of getting users to test the software in the first place under real conditions. of Discovery Studio 1.7 to select customers. "Customers have been pleased with the breadth of functionality in Discovery Studio 1.7 and they are excited about the new component collections for use with Scitegic Pipeline Pilot", commented Mark J. Emkjer, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Accelrys. Jeff Zablocki, Head of Chemistry at CV Therapeutics commented, "We're impressed with how Discovery Studio 1.7 delivers such a broad range of powerful tools for drug discovery in one easy-to-use environment. Our modeling experts were pleased with the time savings realized by having a single environment in which to generate conformers, dock poses, and model pharmacophores. And, they were able to easily deliver graphical results to their counterparts in medicinal chemistry Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacology involved with designing, synthesizing and developing pharmaceutical drugs. with a notable 'wow' factor." Discovery Studio will be commercially available in December 2006. About Accelrys, Inc. Accelrys has over twenty years TWENTY YEARS. The lapse of twenty years raises a presumption of certain facts, and after such a time, the party against whom the presumption has been raised, will be required to prove a negative to establish his rights. 2. of innovation and technology leadership in delivering software and service solutions that transform discovery and development research. A unique combination of expertise in life and materials science materials science Study of the properties of solid materials and how those properties are determined by the material's composition and structure, both macroscopic and microscopic. , informatics, and scientific operating platform technologies lets Accelrys serve a diverse range of clients, including some of the world's leading pharmaceutical, biotechnology, chemical, and nanotechnology research organizations. Accelrys is headquartered in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. . For more information about Accelrys, visit its website at http://www.accelrys.com/. Forward-Looking Statements This press release contains forward-looking statements. Such statements, including statements relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc Discovery Studio 1.7, including its features and potential demand therefore, are subject to risks and uncertainties including, but not limited to, the risks that Discovery Studio 1.7 will not be timely or successfully completed, developed, successfully include all features described herein, or achieve market acceptance, demand relating to Discovery Studio 1.7, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and any subsequent interim filings. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion